Insider Transactions in Q1 2024 at Hca Healthcare, Inc. (HCA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2024
|
Chad J Wasserman SVP and CIO |
SELL
Open market or private sale
|
Direct |
876
-35.73%
|
$289,080
$330.25 P/Share
|
|
Mar 18
2024
|
Chad J Wasserman SVP and CIO |
SELL
Open market or private sale
|
Direct |
344
-12.3%
|
$110,424
$321.97 P/Share
|
|
Mar 18
2024
|
Chad J Wasserman SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,224
-30.45%
|
$400,248
$327.17 P/Share
|
|
Mar 18
2024
|
Chad J Wasserman SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+34.31%
|
$212,100
$101.16 P/Share
|
|
Feb 16
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,005
-31.93%
|
$617,540
$308.55 P/Share
|
|
Feb 16
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,280
+50.0%
|
-
|
|
Feb 16
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,976
-7.81%
|
$608,608
$308.55 P/Share
|
|
Feb 16
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Grant, award, or other acquisition
|
Direct |
5,020
+16.55%
|
-
|
|
Feb 16
2024
|
Chad J Wasserman SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
499
-20.63%
|
$153,692
$308.55 P/Share
|
|
Feb 16
2024
|
Chad J Wasserman SVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+45.75%
|
-
|
|
Feb 16
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,023
-7.48%
|
$315,084
$308.55 P/Share
|
|
Feb 16
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+21.65%
|
-
|
|
Feb 16
2024
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,976
-4.66%
|
$608,608
$308.55 P/Share
|
|
Feb 16
2024
|
Christopher F. Wyatt SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
5,020
+10.59%
|
-
|
|
Feb 16
2024
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,022
-1.91%
|
$314,776
$308.55 P/Share
|
|
Feb 16
2024
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+6.58%
|
-
|
|
Feb 16
2024
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,359
-16.59%
|
$418,572
$308.55 P/Share
|
|
Feb 16
2024
|
Jeffrey E. Cohen SVP-Government Relations |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+31.57%
|
-
|
|
Feb 16
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,212
-14.82%
|
$1,913,296
$308.55 P/Share
|
|
Feb 16
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,980
+17.32%
|
-
|
|
Feb 16
2024
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,950
-21.42%
|
$1,832,600
$308.55 P/Share
|
|
Feb 16
2024
|
Jon M Foster EVP and COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,320
+37.01%
|
-
|
|
Feb 16
2024
|
Richard A Hammett Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,762
-8.95%
|
$542,696
$308.55 P/Share
|
|
Feb 16
2024
|
Richard A Hammett Group President |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+21.83%
|
-
|
|
Feb 16
2024
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,387
-10.26%
|
$9,359,196
$308.55 P/Share
|
|
Feb 16
2024
|
Samuel N Hazen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
78,440
+20.94%
|
-
|
|
Feb 16
2024
|
Mike A Marks EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,022
-26.72%
|
$314,776
$308.55 P/Share
|
|
Feb 16
2024
|
Mike A Marks EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+49.7%
|
-
|
|
Feb 16
2024
|
Timothy M Mc Manus Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,002
-7.87%
|
$616,616
$308.55 P/Share
|
|
Feb 16
2024
|
Timothy M Mc Manus Group President |
BUY
Grant, award, or other acquisition
|
Direct |
6,280
+19.81%
|
-
|
|
Feb 16
2024
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
1,068
-9.31%
|
$328,944
$308.55 P/Share
|
|
Feb 16
2024
|
Sammie S Mosier SVP & Chief Nurse Executive |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+15.32%
|
-
|
|
Feb 16
2024
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Payment of exercise price or tax liability
|
Direct |
1,510
-18.12%
|
$465,080
$308.55 P/Share
|
|
Feb 16
2024
|
Deborah M Reiner SVP - Mktg. & Communications |
BUY
Grant, award, or other acquisition
|
Direct |
5,020
+37.59%
|
-
|
|
Feb 16
2024
|
Bill B Rutherford CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
8,177
-26.87%
|
$2,518,516
$308.55 P/Share
|
|
Feb 16
2024
|
Bill B Rutherford CFO and EVP |
BUY
Grant, award, or other acquisition
|
Direct |
21,980
+41.94%
|
-
|
|
Feb 16
2024
|
Erol R Akdamar Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,561
-33.26%
|
$788,788
$308.55 P/Share
|
|
Feb 16
2024
|
Erol R Akdamar Group President |
BUY
Grant, award, or other acquisition
|
Direct |
7,700
+50.0%
|
-
|
|
Feb 16
2024
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,240
-14.75%
|
$997,920
$308.55 P/Share
|
|
Feb 16
2024
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,420
+30.01%
|
-
|
|
Feb 14
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Bona fide gift
|
Direct |
349
-3.4%
|
-
|
|
Feb 09
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
4,262
-29.37%
|
$1,304,172
$306.21 P/Share
|
|
Feb 06
2024
|
Erol R Akdamar Group President |
BUY
Bona fide gift
|
Indirect |
12,874
+18.87%
|
-
|
|
Feb 06
2024
|
Erol R Akdamar Group President |
SELL
Bona fide gift
|
Direct |
12,874
-100.0%
|
-
|
|
Feb 06
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,423
-6.55%
|
$435,438
$306.82 P/Share
|
|
Feb 06
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,092
+8.79%
|
$361,916
$173.12 P/Share
|
|
Feb 06
2024
|
Bill B Rutherford CFO and EVP |
SELL
Open market or private sale
|
Direct |
6,000
-41.53%
|
$1,860,000
$310.63 P/Share
|
|
Feb 05
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,288
-22.81%
|
$1,329,280
$310.62 P/Share
|
|
Feb 05
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,550
+15.15%
|
$718,200
$84.23 P/Share
|
|
Feb 05
2024
|
Christopher F. Wyatt SVP & Controller |
SELL
Open market or private sale
|
Direct |
4,000
-9.67%
|
$1,248,000
$312.42 P/Share
|